PDS Biotechnology (NASDAQ:PDSB) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a research report sent to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $21.00 price objective on the stock.

PDSB has been the topic of several other reports. B. Riley dropped their price objective on PDS Biotechnology from $11.00 to $9.00 and set a buy rating on the stock in a report on Wednesday, June 12th. Alliance Global Partners upgraded PDS Biotechnology to a strong-buy rating in a report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $14.25.

PDS Biotechnology Stock Performance

Shares of NASDAQ:PDSB opened at $3.12 on Tuesday. The company has a market cap of $114.44 million, a P/E ratio of -2.29 and a beta of 1.88. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.84 and a current ratio of 3.84. PDS Biotechnology has a one year low of $2.53 and a one year high of $6.85. The business’s 50-day simple moving average is $3.38 and its 200 day simple moving average is $3.49.

PDS Biotechnology (NASDAQ:PDSB) last announced its earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same period in the previous year, the company earned ($0.37) EPS. On average, sell-side analysts forecast that PDS Biotechnology will post -1.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PDS Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of PDS Biotechnology by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after acquiring an additional 82,135 shares in the last quarter. Inspirion Wealth Advisors LLC grew its position in shares of PDS Biotechnology by 1.4% in the 2nd quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock worth $1,054,000 after acquiring an additional 4,917 shares in the last quarter. Blair William & Co. IL grew its position in shares of PDS Biotechnology by 204.4% in the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after acquiring an additional 81,743 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of PDS Biotechnology in the 2nd quarter worth approximately $146,000. Finally, Squarepoint Ops LLC acquired a new position in shares of PDS Biotechnology in the 2nd quarter worth approximately $120,000. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.